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Inactivation of Myosin Binding Protein C Homolog in Zebraﬁsh as a
Model for Human Cardiac Hypertrophy and Diastolic Dysfunction
Yau-Hung Chen, PhD; Chiung-Wen Pai, MS; Shu-Wei Huang, MS; Sheng-Nan Chang, MD; Lian-Yu Lin, MD, PhD; Fu-Tien Chiang, MD, PhD;
Jiunn-Lee Lin, MD, PhD; Juey-Jen Hwang, MD, PhD; Chia-Ti Tsai, MD, PhD
Background-—Sudden cardiac death due to malignant ventricular arrhythmia is a devastating manifestation of cardiac hypertrophy.
Sarcomere protein myosin binding protein C is functionally related to cardiac diastolic function and hypertrophy. Zebraﬁsh is a
better model to study human electrophysiology and arrhythmia than rodents because of the electrophysiological characteristics
similar to those of humans.
Methods and Results-—We established a zebraﬁsh model of cardiac hypertrophy and diastolic dysfunction by genetic knockdown
of myosin binding protein C gene (mybpc3) and investigated the electrophysiological phenotypes in this model. We found
expression of zebraﬁsh mybpc3 restrictively in the heart and slow muscle, and mybpc3 gene was evolutionally conservative with
sequence homology between zebraﬁsh and human mybpc3 genes. Zebraﬁsh with genetic knockdown of mybpc3 by morpholino
showed ventricular hypertrophy with increased myocardial wall thickness and diastolic heart failure, manifesting as decreased
ventricular diastolic relaxation velocity, pericardial effusion, and dilatation of the atrium. In terms of electrophysiological
phenotypes, mybpc3 knockdown ﬁsh had a longer ventricular action potential duration and slower ventricular diastolic calcium
reuptake, both of which are typical electrophysiological features in human cardiac hypertrophy and heart failure. Impaired calcium
reuptake resulted in increased susceptibility to calcium transient alternans and action potential duration alternans, which have
been proved to be central to the genesis of malignant ventricular ﬁbrillation and a sensitive marker of sudden cardiac death.
Conclusions-—mybpc3 knockdown in zebraﬁsh recapitulated the morphological, mechanical, and electrophysiological phenotypes
of human cardiac hypertrophy and diastolic heart failure. Our study also ﬁrst demonstrated arrhythmogenic cardiac alternans in
cardiac hypertrophy. ( J Am Heart Assoc. 2013;2:e000231 doi: 10.1161/JAHA.113.000231)
Key Words: animal model • cardiac alternans • diastolic dysfunction • heart failure with normal ejection
fraction • hypertrophy • zebraﬁsh
T he myosin binding protein C (MYBPC) gene (mybpc3)encodes myosin binding protein C, a key constituent of
the thick ﬁlaments localized to doublets in the C-zone of the
A-band of the sarcomere. By binding to myosin, titin, and
actin, MYBPC contributes to maintaining the structural
integrity of the sarcomere and regulates cardiac contractility
and relaxation.1–4 Mutations of mybpc3 gene have been
demonstrated to be associated with a risk of cardiac
hypertrophy and represent one of the common causes of
hypertrophic cardiomyopathy.2–4 Recently, it has also been
demonstrated that genetic variants in human mybpc3 gene
are associated with susceptibility to diastolic heart failure
without overt cardiac hypertrophy.5 Therefore, the function of
MYBPC is closely related to cardiac structural and function
and may be a new therapeutic target in the treatment of
cardiac hypertrophy and diastolic dysfunction.
Diastolic heart failure or heart failure with a normal
ejection fraction (HFNEF) is one of the most important and
common cardiovascular diseases. Clinically, the most com-
mon cause of diastolic heart failure is left ventricular
hypertrophy, resulting either primarily from hypertrophic
cardiomyopathy or secondarily from hypertension and aortic
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stenosis. One of the common causes of death in patients
with left ventricular hypertrophy is malignant ventricular
arrhythmia.6,7 Sudden cardiac death (SCD) due to malignant
ventricular arrhythmia is the most devastating manifestation
of cardiovascular diseases. The Framingham Heart Study
reported that left ventricular hypertrophy was associated
with an increased risk of SCD in a community-based
cohort.7 Because the hemodynamic pathophysiology of
cardiac hypertrophy is well known, the fundamental elec-
trophysiological mechanism of SCD or malignant ventricular
arrhythmia in cardiac hypertrophy is not completely under-
stood.8 Although there are several murine models of cardiac
hypertrophy, such as genetic ablation of mybpc3 or aortic
banding in mice,4,9 the electrophysiological phenotypes of
murine hearts are completely different from those of human
heart due to a very high heart rate and very short action
potential duration (APD), which hinder the evaluation of
cardiac repolarization.10 Because the electrophysiological
phenotypes of large animal heart are closer to those of
human heart,11 currently there has been no well-established
model of cardiac hypertrophy or diastolic dysfunction in
large animals.
Recently, zebraﬁsh has been proved to be a good model in
which to study human cardiac electrophysiology, especially
cardiac repolarization, because its heart rate and action
potential morphology strikingly resemble those of human
heart.10,12 Accordingly, in the present study, based on the role
of MYBPC on cardiac hypertrophy and diastolic dysfunction,2–5
we sought to establish a zebraﬁsh model of human cardiac
hypertrophy and diastolic heart failure by genetic knockdown
of mybpc3. We ﬁrst systematically characterized the status
and expression pattern ofmybpc3 gene in zebraﬁsh, which had
never been reported before. Then we tried to recapitulate the
structural, mechanical, and electrophysiological phenotypes of
human cardiac hypertrophy and diastolic heart failure in this
zebraﬁsh model.
Methods
Cloning of Zebraﬁsh mybpc3 cDNA
For amplifyingmybpc3 cDNA, 3 primer sets [(Mybpc3-1 forward:
5′-ACACTCAACCAGGATGCCAG-3′ and Mybpc3-1 reverse: 5′-TC
AGTGACGGTCTTCTCATCTC-3′), (Mybpc3-2 forward: 5′-TGGCT
GAAGAATGGACAAGAGA-3′ and Mybpc3-2 reverse: 5′-TTC
CTTGCAGTACTCAACACCA-3′), and (Mybpc3-3 forward: 5′-CTCC
ACCAGCGAGCCTATTG-3′ and Mybpc3-3 reverse: 5′-AC-
GTCTCTCTCATTTCTTGATGTCT-3′)] were designed according to
an ensemble contig (ENSDART00000099789) and a National
Center for Biotechnology Information sequence (NM_0010443
9) encoding of a putative zebraﬁsh Mybpc3. According to
reverse transcription–polymerase chain reaction (RT-PCR) exper-
iments, 3 DNA fragments were ampliﬁed, subcloned, and
sequenced.13,14 The presumptiveMybpc3 amino acid sequences
were determined using the Wisconsin Sequence Analysis
Package v.10.0 (GCG). The Gap program of that package was
used for pair comparisons, and the Pileup and Prettybox
programs were used for multiple comparisons. The Clustalw
molecular evolution genetic programwas used for our phylogenic
tree analysis (http://www.ebi.ac.uk/clustalw/).
Zebraﬁsh Embryos, Whole Mount In Situ
Hybridization, Antibody Labeling, and Cryosection
The procedures for zebraﬁsh culture, embryo collection,
ﬂuorescent observation, whole mount in situ hybridization,
antibody labeling, and cryosection have been described
previously.13–15 The designation of developmental stages of
zebraﬁsh followed those of Kimmel et al.16 According to the
guidelines of zebraﬁsh anesthesia and euthanasia,15 there is
no evidence of higher order cognition in zebraﬁsh during the
ﬁrst week of development. During the ﬁrst week of develop-
ment, embryonic movements are simple reﬂexes that do not
provide evidence for a capacity for suffering. Thus, during the
ﬁrst week, zebraﬁsh larvae have not reached the point in
brain development where stimuli can be experienced as
aversive.
Both mybpc3 and cmlc2 were used as probes.17 They were
digoxigenin labeled after their partial DNA fragments were
cloned.
Preparation and Microinjection of Morpholino
Mybpc3-morpholino (MO) (5′-CTCTGGCATCCTGGTTGAGTG
TCCC-3′; Gene Tools) was established according to zebraﬁsh
mybpc3 cDNA sequence for blocking translation. Negative
control MO (5′-CCTCTTACCTCAGTTACAATTTATA-3′) was
designed according to the random nucleotide sequences.
All of these were prepared at stocking concentrations of
1 mmol/L and diluted with double-distilled water to the proper
concentrations (4.5 ng/2.3 nL).
Microscopic Observation of Zebraﬁsh Embryos
All embryos were observed at speciﬁc stages under a
microscope (DM 2500; Leica) equipped with Nomarski
differential interference contrast optics and a ﬂuorescent
module with a GFP ﬁlter cube (Kramer Scientiﬁc).
Photographs of embryos at speciﬁc stages were taken with
a CCD (DFC490; Leica). Measurement of myocardial wall
thickness in the embryo heart was performed as previously
reported,18 using a camera with high temporal (14 frames/s)
and spatial (518493456 pixels) resolutions (Canon
EOS-1DX).
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Evaluation of In Vivo Systolic and Diastolic
Functions of the Zebraﬁsh Embryo Heart
We evaluated the systolic and diastolic functions in the
zebraﬁsh embryo heart using the automatic video
edge-detection system.19 In brief, SoftEdge (IonOptix Corpo-
ration) was used to measure real-time length via contrast
analysis of digitized image data. Edge detection was based
on image intensity, and image contrast was enhanced using
the video gain and offset controls. The signal was calibrated
using a standard millimeter graticule. The calculated values
were veriﬁed by conventional velocity measurement obtained
from 2-dimensional images using a camera with high
temporal (14 frames/s) and spatial (518493456 pixels)
resolutions (Canon EOS-1DX). Velocity values were
expressed as micrometers per second for myocardial wall
velocity in systole and diastole to represent the systolic and
diastolic functions, respectively.
Extraction of Zebraﬁsh Embryo Heart and In Vitro
Electrophysiological Recordings
The heart of the embryo was dissected from the thorax en
bloc by using ﬁne forceps and then transferred to the
recording chamber. Only spontaneously beating whole hearts
were studied. All experiments were performed at room
temperature. The recording chamber was superfused with
solution containing (in mmol/L) NaCl 140, KCl 4, CaCl2 1.8,
MgCl2 1, glucose 10, and HEPES 10, pH 7.4.
10 Action
potentials were recorded by the microelectrode and disrupted
patch method, as previously reported.10 Action potentials
were measured by using an ampliﬁer (Axopatch 200B; Axon
Instrument) and digitized with a 12-bit analog-to-digital
converter (Digidata 1440A Interface; Molecular Devices).
Resting action potentials were ﬁrst recorded and then
triggered by incrementally injecting pulses of depolarizing
current. For calcium transient recording, the embryo hearts
were stained with Fluo 3–acetoxymethyl ester (5 lmol/L;
Molecular Probes) and then recorded with an inverted
confocal microscope (LSM 510; Carl Zeiss) as previously
recorded.20 For ﬂuorescence excitation, the 488-nm band of
an argon laser was used. Emission was recorded using a
long-pass LP 515 ﬁlter set.20
Measurement of APD and Calcium Transient
Alternans and Calcium Transient Decay Rate
Alternans of APD (APD-ALT) and calcium transient (Ca-ALT)
were determined by measuring differences in local APD and
calcium transient amplitude on consecutive beats as previ-
ously reported.21 The APD-ALT (in ms) and Ca-ALT (in %) were
plotted against the pacing rates (PRs).
The calcium transient decay rate was measured as previ-
ously reported.21,22 The calcium level was reported as F/F0,
where F0 was the resting or diastolic ﬂuorescence level. To
quantify the calcium transient decay rate, the decay portion of
the calcium transient (from 30% to 100% of decline phase) was
ﬁt to a single exponential function whose time constant, s, was
used to measure calcium transient decay rate.22,23
Statistical Methods
All data were expressed as meanSD. Continued data from
independent group were compared by using the Mann-Whit-
ney U test. The Cochran-Armitage test was used to test a
trend of the dose–response relationship between frequencies
of phenotypic abnormalities and dose of Mybpc3-MO injec-
tion. A P value <0.05 was considered statistically signiﬁcant.
Results
Cloning of Zebraﬁsh mybpc3 cDNA and
Comparison of Deduced Amino Acid Sequences
In searching the GenBank database, we found 1 putative
zebraﬁsh mybpc3 sequence (NM_001044349). After RT-PCR
and DNA sequencing, we found there exist 3 mybpc3
transcription variants (mybpc3-tv1, -tv2, and -tv3) during
zebraﬁsh early embryogenesis (Figure 1A). After sequence
cross-comparison, we found there are 5 differences between
human and zebraﬁsh mybpc3 transcripts (indicated by arrows
1 to 5). For example, all zebraﬁsh mybpc3 transcription
variants lack the second exon (arrow 1) but possess 2 extra
exons (arrows 3 and 5); zebraﬁsh mybpc3-tv2 and -tv3 have an
extra exon (arrows 4 and 2) in comparison with mybpc3-tv1.
The deduced zebraﬁsh Mybpc3-tv1 amino acid sequence
consists of a 1276–amino acid polypeptide. The zebraﬁsh
Mybpc3-tv1 polypeptide shares sequence identities of 63%,
61%, 62%, 63%, 61%, 68%, and 70% with the reported Mybpc3
of human, chimpanzee, bovine, mouse, rat, chicken, and
Xenopus, respectively. We used the Clustalw program to
determine the phylogenic similarities between zebraﬁsh
Mybpc3-tv1 and other known species. The phylogenic tree
generated by the program showed that zebraﬁsh Mybpc3-tv1
possesses a unique pattern, different from those of higher
vertebrates (data not shown).
We therefore examed the expression proﬁle of 3 individual
mybpc3 transcripts by the use of RT-PCR and found that
mybpc3-tv1 signals are detectable from 18 to 96 hours
postfertilization (hpf) (except for 48 hpf); mybpc3-tv2 signals
are detectable at 18 to 48 hpf; and mybpc3-tv3 signals are
detectable at 48 to 96 hpf (Figure 1B). These observations
suggest that these 3 zebraﬁsh mybpc3 transcripts have a
unique proﬁle during zebraﬁsh early embryogenesis.
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Zebraﬁsh mybpc3 Expressed in Heart and Slow
Muscle
We next determined the overall expressions of 3 mybpc3
mRNAs (combinations ofmybpc3-tv1, -tv2, and -tv3) in zebraﬁsh
embryos by using whole mount in situ hybridization. During
early embryonic development, mybpc3 expressions ﬁrst
became evident in the developing somites and heart tube
(Figure 2A and 2B). At later stages, mybpc3 mRNA remained
restricted to the heart and skeletal muscle throughout
embryogenesis (Figure 2C and 2D). Cryosection results showed
that mybpc3mRNAs expressions are restricted in the ventricle
and slow muscle but faint in the atrium (Figure 2E through 2J).
Loss of mybpc3 Leads to Cardiac Hypertrophy
and Diastolic Heart Failure in Zebraﬁsh
To investigate the role of MYBPC in vivo, we knocked zebraﬁsh
mybpc3 down by injecting morpholino-modiﬁed antisense
oligonucleotides directed against translational start site (My-
bpc3-MO) into one-cell–stage zebraﬁsh embryos. We found
that negative control MO or Mybpc3-MO–injected embryos
showed normal heart morphogenesis during the ﬁrst 24 hours
of development (24 hpf). By 72 hpf, Mybpc3-MO–injected
zebraﬁsh showed pericardial edema and enlarged cardiac
chambers as determined in bright ﬁeld imaging (Figure 3A and
3B), which recapitulated typical features of human heart
failure. In human heart failure, edema often occurs in
dependent parts, such as bilateral lower legs. In embryonic
ﬁsh, the pericardiac sac is the dependent part, and heart failure
usually manifests as pericardial edema.10 The ventricular wall
thickness was also increased in the Mybpc3-MO–injected
zebraﬁsh (diastolic wall thickness 15.10.8 lm in morphants
and 13.40.7 lm in control embryos; P=0.009), resembling
human ventricular hypertrophy. Immunostaining using both
atrial and ventricular speciﬁc markers showed mild enlarge-
ment of the ventricle but signiﬁcant enlargement of the atrium
(Figure 3C and 3D), a typical feature of human diastolic
dysfunction.24,25 Histologically, the Mybpc3-MO–injected
heart showed ventricular hypertrophy (Figure 3E and 3F).
Finally, increased expression of sarcomere proteins has been
used as a marker of cardiac hypertrophy.26,27 Accordingly, we
also found that Mybpc3-MO–injected hearts showed an
increased expression of sarcomere protein, cardiac myosin
light chain 2 (cmlc2), as determined with nonquantitative in
situ hybridization (Figure 3G and 3H).
Figure 1. Gene structures and expression proﬁles of mybpc3 during zebraﬁsh early embryogenesis. A, Schematic illustration of human MYBPC3
gene and 3 zebraﬁsh mybpc3 transcripts. The differences between human and zebraﬁsh mybpc3 are marked by the red box and arrows. B,
Expression proﬁles of 3 zebraﬁsh transcriptional variants (mybpc3-tv1, -tv2, and -tv3). hpf indicates hours postfertilization; MYBPC, myosin binding
protein C; tv, transcription variant.
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Interestingly, the frequencies of phenotypic abnormalities
in consequence of Mybpc3-MO injection followed a
dose-dependent manner (Table). At 2.0 ng, 36.1% (total cases
in triplicate experiments, n=88) of the surviving embryos
(n=244) displayed heart failure phenotypes, and at 3.0 ng, the
percentage increased to 46.4% (n=116; Table) (P=0.011 for
trend test).
We further characterized the alternation of mechanical
function after loss of mybpc3 function. The ventricular systolic
functions were comparable between the negative control MO
or Mybpc3-MO–injected embryos, as determined by mea-
surement of maximal ventricular systolic velocity
(22664 lm/s in morphants and 21452 lm/s in control
embryos; P>0.05). However, Mybpc3-MO–injected embryos
showed signiﬁcantly impaired ventricular diastolic function, as
determined by measurement of maximal ventricular diastolic
relaxation velocity (21358 lm/s in morphants and
29765 lm/s in control embryos; P=0.043). These features
resembled those of human heart failure with preserved left
ventricular ejection fraction (HFNEF) or diastolic dysfunction.
Taken together, the Mybpc3-MO–injected ﬁsh showed
typical features of human diastolic heart failure with dilated
atrium, ventricular hypertrophy, and preserved ventricular
systolic function.24,25
Mybpc3-MO–Injected Zebraﬁsh Have a Longer
APD and Increased Susceptibility to
Arrhythmogenic APD-ALT
We then characterized the electrophysiological phenotypes
after loss of mybpc3 function. The action potentials of the
zebraﬁsh embryo hearts were recorded under in vitro
conditions (Figure 4). The resting APD was longer in the
Mybpc3-MO–injected heart, compared with that of the control
ﬁsh heart (mean APD 31631 ms versus 27825 ms,
P=0.007). Interestingly, prolonged APD is the pathognomic
electrophysiological feature of human cardiac hypertrophy
and heart failure.28,29
Recently, it has been demonstrated that repolarization or
APD-ALT is central to genesis of malignant ventricular arrhyth-
mia or ventricular ﬁbrillation and is a highly sensitive marker of
susceptibility to SCD.30 We sought to investigate whether loss
of mybpc3 function led to increased susceptibility to APD-ALT.
Incremental pacing was performed to evaluate the relationship
between APD-ALT and PR in control and Mybpc3-MO–injected
hearts (Figure 5). In Mybpc3-MO–injected hearts, there was a
leftward shift in the APD-ALT–to–PR relationship (Figure 5B). In
other words, at each PR, the magnitude of ALT was always
greater in the Mybpc3-MO–injected hearts, indicating greater
susceptibility to APD-ALT .21 Therefore, in addition to ventric-
ular hypertrophy and diastolic heart failure, Mybpc3-MO–
injected hearts may be more susceptible to ventricular
arrhythmia or ﬁbrillation because of greater susceptibility to
APD-ALT.
Mybpc3-MO–Injected Zebraﬁsh Show Slower
Diastolic Calcium Decay and Increased
Susceptibility to Ca-ALT
Accumulating evidence has shown that APD-ALT arise
primarily from Ca-ALT in both intact whole hearts31 and in
vitro cardiomyocytes.21 In the next step, we tried to
investigate the calcium dynamics in the Mybpc3-MO–injected
hearts.
The calcium transient of the Mybpc3-MO–injected hearts
showed characteristic features as seen in mammalian
Figure 2. mybpc3 expression patterns during zebraﬁsh embryogenesis. A through D, Whole mount in situ hybridization of 24-hpf-, and
48-hpf-embryos shows that mybpc3 expresses in heart and somites. E and F, Cryosectioning showed that the expressions mybpc3 were restricted
in ventricle, atrium, and slow muscles. G through J, By 72 hpf, mybpc3 signals were still detectable in ventricle and atrium but were
down-regulated in muscle. A indicates atrium; hpf, hours postfertilization; mybpc, myosin binding protein C; V, ventricle.
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hypertrophic and failure hearts.29,32 The rising time was
longer, and the peak calcium was smaller (Figure 6). The
decay rate of calcium transient was also slower, with a
larger time constant, indicating defective calcium reuptake
and cycling.21,23 Defective intracellular calcium cycling may
directly contribute to Ca-ALT.21,23,31 We then sought to
investigate whether Mybpc3-MO–injected hearts also had
increased susceptibility to Ca-ALT.
Incremental pacing was performed to evaluate the rela-
tionship between Ca-ALT and PR in control and Mybpc3-MO–
injected hearts (Figure 7). Like in the study of APD-ALT, in
Mybpc3-MO–injected hearts, there was a leftward shift in the
Ca-ALT–to–PR relationship, indicating greater susceptibility to
Ca-ALT. Interestingly, the developments of APD-ALT and
Ca-ALT were closely related and coupled, and both are highly
rate dependent.
In summary, the Mybpc3-MO–injected hearts showed
characteristic electrophysiological features with greater sus-
ceptibility to arrhythmogenetic cardiac ALT as those seen in
mammalian hypertrophic and failure heart.
Discussion
In the present study, we have systematically characterized the
expression of mybpc3 in zebraﬁsh and demonstrated that loss
of mybpc3 in zebraﬁsh recapitulates the morphological,
mechanical, and electrophysiological phenotypes of human
cardiac hypertrophy and diastolic heart failure. We have also
ﬁrst shown that mybpc3 gene is evolutionally conservative
and is an essential gene for the cardiac development of
vertebrates, because loss of mybpc3 leads to severe cardiac
phenotypes. This is also the ﬁrst study to demonstrate an
increased susceptibility to arrhythmogenic cardiac ALT in
a zebraﬁsh model of cardiac hypertrophy and diastolic
dysfunction.
In the characterization of mybpc3 gene expression in
zebraﬁsh, we found sequence homology between human and
zebraﬁsh mybpc3 genes. Furthermore, ablation of mybpc3
gene expression results in similar phenotypes in zebraﬁsh and
human hearts. These results implicate that zebraﬁsh heart is a
feasible model system in which to dissect the detailed
pathophysiological mechanism of human cardiovascular dis-
eases. Previously, Norton et al33 reported a similar approach
to induce heart failure in zebraﬁsh to study the function of
BCL2-associated athanogene 3 gene in humans. However, in
this study, only mechanical phenotypes were characterized.
The most devastating phenotype of human heart failure is
ventricular arrhythmia or SCD. Therefore, correlating the
electrophysiological phenotype to mechanical phenotype is
important and clinically relevant. Notably in the present study,
we characterized both the mechanical and electrophysiolog-
ical phenotypes in the zebraﬁsh embryo heart and success-
fully established an animal model and platform in which to
study the electrophysiological mechanism of SCD for human
cardiac hypertrophy and diastolic heart failure.
Figure 3. Knockdown of mybpc3 in zebraﬁsh embryos leads to
cardiomyopathy. A and B, Morphology of the embryonic zebraﬁsh
heart (72 hpf) with Mybpc3-MO injection or control. Arrow indicates
the position of atrium. C and D, Embryos derived from control or
Mybpc3-MO–injected group were stained with different antibodies
MF20 (red) and S46 (green), and results reveals that Mybpc3
knockdown causes enlarged cardiac chambers, especially the atrium.
Dashed and solid lines marked the morphology of atrium and
ventricle, respectively. E and F, Hematoxylin and eosin (H&E) staining
shows that mybpc3-morphants have ventricular hypertrophy and
thinner atrial wall. G and H, Whole mount in situ hybridization using a
cardiac-speciﬁc marker cmlc2 as probes and showing that inactiva-
tion of mybpc3 causes increased heart size. H′, Ventral view of H. A
indicates atrium; hpf, hours postfertilization; MO, morpholino; mybpc,
myosin binding protein C; V, ventricle.
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Previous studies have shown that loss of mybpc3 in
mammalian hearts leads to cardiac hypertrophy,3,4 which is
often demonstrated by cardiac imaging, such as echocardiog-
raphy or magnetic resonance imaging. This kind of imaging
modality is not feasible in the embryonic zebraﬁsh heart.
However, in the present study, we provided several lines of
evidence to demonstrate cardiac hypertrophy in the small
embryonic zebraﬁsh heart, such as increased myocardial wall
thickness and increased expression of sarcomere protein
cmlc2 by nonquantitative measurement.26,27 Other convincing
data to prove the presence of ventricular hypertrophy in our
zebraﬁsh model are marked diastolic dysfunction and dilated
atrium. It has been shown in humans that left ventricular
hypertrophy is often accompanied by ventricular diastolic
dysfunction and dilated atrium.24,25 Therefore, the present
zebraﬁsh model of mybpc3 knockdown may be a good model
in which to study the pathophysiology of human cardiac
hypertrophy or diastolic dysfunction, such as the electrophys-
iological abnormalities as demonstrated in the present study.
Although there have been several murine models of cardiac
hypertrophy,4,9,10 using zebraﬁsh as a model system provides
major advantages of easy genetic manipulation, high through-
put, and efﬁcient data proﬁling. Moreover, accumulating
evidence has shown that the electrophysiological phenotypes
of zebraﬁsh heart are much closer to those of human heart
than are the murine hearts.10,12
It has been demonstrated that cardiac ALT, that is, beat-to--
beat alternation of cardiac repolarization or APD, is a highly
sensitive marker of susceptibility to SCD.30,34,35 Beat-to-beat
alternation of APD, or APD-ALT, produces a repolarization
gradient or spatial heterogeneity of refractoriness and facilitates
the occurrence of conduction block and the initiation of
reentrant arrhythmia. Accumulating evidence has showed that
this arrhythmogenic APD-ALT may arise from defective calcium
reuptake kinetics and Ca-ALT.21,30,31 In the present study, we
showed that zebraﬁshheartswithmybpc3knockdowndisplayed
defective calcium cycling. Accordingly, in addition to cardiac
hypertrophy and diastolic dysfunction, these hearts showed
increased susceptibility to Ca-ALT and APD-ALT. Again, these
results prove the concept that zebraﬁsh heart could be used as a
model system in which to study the molecular mechanism of
ventricular arrhythmia or SCD related to cardiac hypertrophy.
For example, selective gene manipulation may be performed in
the future to test whether hypertrophy-related arrhythmogenic
cardiac ALT could be abolished or prevented. Then, this gene
may become the target for subsequent drug development to
treated hypertrophy-related SCD.
Table. Morphological Phenotypes of Zebraﬁsh Embryos Derived From Fertilized Eggs Injected With Mybpc3-MO
Injection Dose
(per Embryo), ng
Injected
Embryos
No. of Surviving Embryos*
(Survival Rates), %†
Embryos Without
Defective Heart Phenotype, %‡
Embryos With Defective
Heart Phenotype, %‡
2.0 368 244 (66.3) 156 (63.9) 88 (36.1)
2.5 295 205 (69.5) 128 (62.4) 77 (37.6)
3.0 380 250 (65.8) 134 (53.6) 116 (46.4)
3.5 327 159 (48.6) 93 (58.5 66 (41.5)
4.0 397 126 (31.7) 74 (58.7) 52 (41.3)
MO indicates morpholino; MYBPC, myosin binding protein C.
*Total number of the surviving embryos in triplicate experiments.
†Survival rates indicate the number of surviving embryos among the number of injected embryos.
‡Percentages indicate the number of embryos without or with defective heart phenotype among the numbers of surviving embryos.
Figure 4. Explanted Mybpc3-MO–injected hearts have longer
action potential durations (APDs). A, Representative action potentials
of Mybpc3-MO–injected (MYBPC3 MO) and control (CTL) hearts. The
MYBP MO heart has a longer APD. B, The mean APD was longer in
the MYBPC3 MO hearts than the control (CTL) hearts. *P<0.05 vs
controls. MO indicates morpholino; mybpc, myosin binding protein C.
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We also ﬁrst demonstrated that arrhythmogenic cardiac
ALT could be induced in the hypertrophic heart, providing the
possible electrophysiological mechanism of increased risk of
SCD in patients with cardiac hypertrophy.6,36,37 Our results
also implicate the possibility of increased susceptibility to
SCD or severe ventricular arrhythmia in patients with diastolic
heart failure or HFNEF, which has never been addressed
before. Our results also imply that screening of mybpc3
genetic variation may be one of the strategies for SCD risk
stratiﬁcation in patients with diastolic heart failure or HFNEF.
Chen et al38 also reported a mouse model with conditional
knockout of mbyc3 in the heart. The cardiac phenotypes of
this mouse model were very close to those of our zebraﬁsh
model, such as cardiac hypertrophy, cardiac diastolic dys-
function, and preserved systolic function. This may be another
model in which to study the electrophysiological mechanism
of SCD in cardiac hypertrophy or HFNEF. However, no
electrophysiological phenotypes had been characterized in
this murine cardiac hypertrophy model. As mentioned previ-
ously, it is very difﬁcult to study cardiac repolarization in the
mouse heart because of the extremely short APD.
Conclusions
We characterized the functional role of mybpc3 gene in terms
of cardiac morphological, mechanical, and electrophysiolog-
ical phenotypes and established the fundamental role of
MYBPC in the mechanism of cardiac hypertrophy, diastolic
dysfunction, and arrhythmogenic cardiac ALT. The results of
the present study provide the rationale to develop novel
Figure 5. Explanted Mybpc3-MO–injected hearts have an increased susceptibility to action potential duration alternans (APD-ALT).
A, Representative action potential tracings at 350 ms pacing cycle length for both Mybpc3-MO–injected (MYBPC3 MO) and control (CTL)
hearts are shown. Signiﬁcant APD alternans is seen in the MYBPC3 MO heart (lower panel), but not in the CTL heart (upper panel). B, Summary
data for all experiments demonstrating the relationship of pacing rate (PR) and alternans from CTL and MYBPC3 MO hearts are shown. In MYBPC3
MO hearts, more APD-ALT was observed at each PR tested, with a leftward shift in APD-ALT–to–PR relationship. MO indicates morpholino; mybpc,
myosin binding protein C.
Figure 6. Explanted Mybpc3-MO–injected hearts have a slower
calcium reuptake kinetics. A, Representative calcium transients from
control (CTL) and Mybpc3-MO–injected (MYBPC3 MO) hearts are
shown. Calcium transients were expressed as F/F0 (ﬂuorescence
level [F] normalized to diastolic ﬂuorescence level [F0]). The decay
portion of the calcium transient (from 30% to 100% of decline phase)
was marked as a red curve and was ﬁt to a single exponential
function whose time constant, s, was used to measure Ca2+ decay. B,
Summary data of s and calcium transient amplitude in CTL and
MYBPC3 MO hearts at a baseline pacing rate (PR) of 120 bpm. The s
was larger in MYBPC3 MO hearts than in CTL hearts, reﬂecting a
slower Ca2+ decay rate. The calcium transient amplitude was also
signiﬁcantly smaller in the MYBPC3 MO hearts than in the CTL
hearts. *P<0.05 vs controls. MO indicates morpholino; mybpc,
myosin binding protein C.
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therapy targeting MYBPC to prevent SCD in cardiac hyper-
trophy or diastolic heart failure.
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